Pharmaceutical Executive-01-01-2017

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Pharm Exec speaks with Spanish-born Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, who shares her steady-eyed approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.

Connected ecosystems will change the future of healthcare. Three key value drivers are outlined.

Rethinking views on limited-efficacy drug approvals may be in order.

With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.

Health reform, pricing pressures will shape drug marketing and development in 2017.

The seven ways for pharmas to ensure successful execution of action steps following brand "war games."

It's time to take advantage of a nascent technology embrace taking hold among market insights professionals.

This sponsored supplement was produced by Focus ReportsProject Publisher: Mariuca GeorgescuProject Director: Carla Verdera MateuCoordinators: Brandon Mourich & Julija LukaityteProject Assistants: Zoë BerginSenior Editor: Louis HaynesEditor: Patrick Burton

Click the title above to open the Pharmaceutical Executive January 2017 issue in an interactive PDF format.